Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: A single‐center cohort study
暂无分享,去创建一个
H. Bueno | J. Aguado | C. Lumbreras | J. Pablos | M. Fernández-Ruiz | J. Martínez-López | R. Laguna-Goya | R. García-García | M. Catalán | F. López-Medrano | M. Lizasoáin | R. Juan | C. de la Calle | M. Ripoll | H. Trujillo | M. Asín | J. Origüen | J. M. Caro-Teller | Carlos Gómez | G. M. de la Calle | F. López‐Medrano | Hernando Trujillo | R. S. Juan
[1] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.
[2] J. Badie,et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients , 2020, Médecine et Maladies Infectieuses.
[3] A. Omrani,et al. Tocilizumab for the treatment of severe coronavirus disease 2019 , 2020, Journal of medical virology.
[4] S. Baldovino,et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. , 2020 .
[5] Xiaohu Zheng,et al. Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.
[6] Reem A Mustafa,et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] R. Magistroni,et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine , 2020, American Journal of Transplantation.
[8] M. Ramesh,et al. Acute hypertriglyceridemia in patients with COVID‐19 receiving tocilizumab , 2020, Journal of medical virology.
[9] J. Martinez-Llorens,et al. Lack of dyspnea in patients with Covid‐19: another neurological conundrum? , 2020, European journal of neurology.
[10] A. Gasbarrini,et al. Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.
[11] F. A. Lagunas-Rangel,et al. High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients , 2020, Journal of medical virology.
[12] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[13] Zhiguang Zhou,et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? , 2020, Journal of Autoimmunity.
[14] Dong Liu,et al. Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.
[15] Jonathan H. Morgan,et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support , 2020, medRxiv.
[16] M. Orsi,et al. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab , 2020, Diagnostic and Interventional Imaging.
[17] Guiqiang Wang,et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality , 2020, International Journal of Antimicrobial Agents.
[18] Sharukh Lokhandwala,et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.
[19] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[20] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[21] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[22] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[23] D. Teachey,et al. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome , 2019, Expert review of clinical immunology.
[24] A. Kimura,et al. IL‐6: Regulator of Treg/Th17 balance , 2010, European journal of immunology.
[25] G. Bernard,et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. , 2007, Chest.
[26] Ali Danesh,et al. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome , 2007, Journal of Virology.
[27] R. Henderson,et al. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. , 1996, The European respiratory journal.
[28] R. Zinkernagel,et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.
[29] R. Smith,et al. Elevated lactate dehydrogenase values in patients with Pneumocystis carinii pneumonia. , 1988, Chest.
[30] Acls Pals,et al. DEPARTMENT OF EMERGENCY MEDICINE , 2009 .